psilocybin + zolpidem + modafinil

This is a combination of three pharmacologically distinct drugs: - **Psilocybin** is a classic serotonergic psychedelic that acts primarily as an agonist at the serotonin 5-HT2A receptor, producing alterations in perception, mood, and cognition. It is being investigated for psychiatric and pain-related indications. - **Zolpidem** is a non-benzodiazepine hypnotic agent that acts as an agonist at the GABA-A receptor (specifically the omega-1 subtype), used primarily for short-term treatment of insomnia. - **Modafinil** is a wakefulness-promoting agent (stimulant) indicated for narcolepsy, sleep apnea, and shift work disorder. Its mechanism involves inhibition of dopamine reuptake and activation of orexin neurons; it also affects glutamatergic and GABAergic neurotransmission[4][5]. This specific combination has been studied in early-phase clinical research to evaluate its effects on chronic low back pain—particularly to assess whether psilocybin therapy combined with zolpidem (a sedative) and modafinil (a stimulant) can help patients cope more effectively with chronic pain by targeting both psychological distress and sleep/wake regulation[1]. The rationale appears to be leveraging psilocybin’s potential for emotional/psychological benefit while using zolpidem to manage sleep disturbances and modafinil to address daytime fatigue or cognitive impairment.